NASDAQ • Last print unknown ago
$36.05—Stale · unknown old
Biotech Rally in Its Early Innings
Moderna Q2 Earnings, Buyback Plans Lift Biotech ETFs
Pfizer Biohaven Acquisition Sparks Hope of More Biotech M&A
Battered Biotech Space Now Unbelievably Inexpensive
Biotech ETFs Muddled Despite Amgen Strength
Cap-Weighting Crucial When Indexing Biotech
Biotech Firms Partner to Advance Therapeutic Medicine
An ETF to Capture Promising Biotech Innovators
Biotech Stocks and ETFs Can Get Their Grooves Back
Expect More Biotech Consolidation Activity in 2022
Moderna's Omicron Booster Strategy Lifts Biotechnology ETFs
Position for Biotech Rebound With Quality Names
An ETF to Watch for Amidst the Vaccine Push
A Biotech ETF to Track Nasdaq's Industry-Setting Benchmark
The Biotech Trek: A Short History from 1993 to 2021